Business · Companies · 8 hrs ago

Swiss officials and drugmakers dispute whether US price plans threaten medicine access

Swiss officials and drugmakers dispute whether US price plans threaten medicine access

US President Donald Trump wants lower medicine prices, and the pharmaceutical industry says this could put pressure on prices in Switzerland.

Swiss price watchdog Stefan Meierhans and industry leader Marcel Plattner disagree about what that means for patients.

Plattner says US plans could make companies less willing to launch medicines in Switzerland, because some prices there may affect prices in the US.

Meierhans says the plans are uncertain, and Switzerland is not among the lowest-priced countries in two of the US programmes he discusses.

The two sides also dispute how many new medicines are reaching Swiss patients: Plattner says 35 per cent of innovative products were available in Switzerland, compared with 58 per cent in Germany and 88 per cent in the US.

He says companies plan to delay eight product launches in Switzerland in 2026 and have cancelled three.

Meierhans says claims that US plans will reduce access are still speculation, since the programmes and company agreements remain unclear.

The dispute matters because delayed launches could limit patients' access to new treatments.

The effect on Swiss medicine access remains uncertain, as the US plans and legal challenge are unresolved.

1 source

Related

What people are saying

Stefan MeierhansSwiss price supervisor
We cannot estimate how large the effects on Switzerland will be.
via NZZ
The price is not the only thing that determines how quickly you get access to a medicine.
via NZZ
Marcel PlattnerPresident of the pharmaceutical association Vips
For 2026, we see that our companies will not initially introduce eight products.
via NZZ
In the United States, 88 percent of all innovative products were available in recent years. In Germany it was 58 percent, and in Switzerland just 35 percent.
via NZZ